Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials Unit


Trial Name

SCHRIFT - Short Chemo RadioImmunotherapy in Follicular Lymphoma Trial of 90Y Ibritumomab tiuxetan (Zevalin) as therapy for first and second relapse in Follicular Lymphoma.


A prospective phase II open label, non-randomised trial looking at short chemo-radioimmunotherapy in follicular lymphoma using Zevalin.


Primary objective:

Secondary objectives:


This is a multi-centre, open labelled single arm, non-randomised prospective study to assess the preliminary safety and efficacy of abbreviated immunochemotherapy (3 cycles of CHOP-R) followed by 90Y ibritumomab tiuxetan (Zevalin) in patients with follicular NHL who have experienced a first or second relapse.




Sixty patients in first or second relapse of follicular NHL will be enrolled in the study. For patients who have received R-chemotherapy regimens, they must have relapsed 6 months or more after R-Chemotherapy. Patients who relapse within 6 months of R-chemotherapy or those who have primary refractory disease are excluded from the study .

Contact Details

All Trial enquiries should be addressed to

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.